Last reviewed 2026-04-20 · How we verify

optimized oral treatment

At a glance

Approved indications

No approved indications tracked.

Common side effects

• Nausea
• Headache
• Vomiting
• Insomnia
• Diarrhoea
• Dizziness
• Abdominal pain upper
• Arthralgia
• Hyperuricaemia
• Nasopharyngitis
• Tinnitus
• Palpitations

Key clinical trials

• Virtual Reality for Postoperative Recovery After Major Abdominal Surgery (NA)
• Enhanced Recovery After Surgery (ERAS) in Patients With Peritoneal Carcinomatosis Undergoing Cytoreductive Surgery With or Without HIPEC (NA)
• Study of a Single Dose of Pretomanid Added to an Optimized Background Regimen in Children With Rifampicin-Resistant Tuberculosis (PHASE1)
• A Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination With Osimertinib as First-Line Treatment in Adult Participants With Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer (PHASE2, PHASE3)
• A Study of Soticlestat in Adults and Children With Rare Epilepsies (PHASE2)
• Study to Evaluate the Safety and Efficacy of Lenacapavir (GS-6207) in Combination With an Optimized Background Regimen (OBR) in Heavily Treatment Experienced Participants Living With HIV-1 Infection With Multidrug Resistance (PHASE2, PHASE3)
• A Clinical Study to Test if an Investigational Treatment Called BNT314 When Used in Combination With Another Investigational Treatment BNT327 and Chemotherapy, is Beneficial and Safe for Patients With Advanced Colorectal Cancer (PHASE1, PHASE2)
• A Study of Gilteritinib, Venetoclax and Azacitidine as a Combined Treatment for People Newly Diagnosed With Acute Myeloid Leukemia (PHASE1, PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.